AGENUS INC (AGEN)
D
Pipeline Grade
Financial Position (from SEC Filings)
$35.0M
Cash & Equivalents
$36.0M
Quarterly Burn Rate
3 mo
Est. Cash Runway
$140M
Market Cap
Estimated from most recent SEC quarterly filing. View SEC filings
Drug Pipeline (0 Assets)
No drugs indexed yet. Pipeline data is populated from ClinicalTrials.gov and openFDA.
Upcoming Catalysts
| Date | Event | Drug |
|---|---|---|
| 2026-08-04 | Phase2 Readout | — |
| 2026-10-01 | Phase2 Readout | — |
| 2026-12-01 | Phase2 Readout | — |
| 2026-12-01 | Phase2 Readout | — |
| 2027-01-01 | Phase1 Readout | — |
| 2027-04-07 | Phase2 Readout | — |
Active Clinical Trials (24)
| NCT # | Title | Phase | Status | Enrollment |
|---|---|---|---|---|
| NCT07152821 | Botensilimab + Balstilimab vs Best Supportive Care as Therapy in Chemo-refractory, Unresectable, Colorectal Adenocarcino... | PHASE3 | Recruiting | 834 |
| NCT06279130 | Pan-tumor Neoadjuvant Basket Study of Immune Check-point Inhibition and Novel Immuno-oncology Combinations | PHASE3 | Recruiting | 133 |
| NCT06346197 | Combination of Immune Checkpoint in Locally Advanced or Metastatic MSI/dMMR Esogastric Adenocarcinomas | PHASE3 | Recruiting | 132 |
| NCT05318469 | Ivermectin in Combination With Balstilimab or Pembrolizumab in Patients With Metastatic Triple Negative Breast Cancer | PHASE2 | Recruiting | 34 |
| NCT07227636 | A Study of Botensilimab and Balstilimab for Colorectal Cancer With ctDNA+ After Surgery and Chemotherapy | PHASE2 | Recruiting | 284 |
| NCT05632328 | AGEN1423 and Botensilimab w/ or w/o Chemo in PDAC | PHASE2 | Active Not Recruiting | 24 |
| NCT06782555 | A Study of Evofosfamide in Combination with Zalifrelimab and Balstilimab | PHASE2 | Recruiting | 71 |
| NCT06843434 | A Study of Botensilimab and Balstilimab for Rectal Adenocarcinoma | PHASE2 | Recruiting | 40 |
| NCT05864534 | Phase 2a Immune Modulation With Ultrasound for Newly Diagnosed Glioblastoma | PHASE2 | Recruiting | 25 |
| NCT05608044 | A Study of Botensilimab and Balstilimab for the Treatment of Colorectal Cancer | PHASE2 | Active Not Recruiting | 234 |
| NCT06843551 | The Miami "EMPIRE" Trial - Eradication of Metastatic Pancreatic Cancer With Immuno-Radiation | PHASE2 | Recruiting | 20 |
| NCT04028063 | Doxorubicin Plus Dual Checkpoint Blockade for Soft Tissue Sarcomas | PHASE2 | Active Not Recruiting | 65 |
| NCT05571293 | Combination Immunotherapy in Colorectal Cancer | PHASE2 | Active Not Recruiting | 26 |
| NCT05205330 | Vorbipiprant (CR6086) / Balstilimab (AGEN2034) Combination in Stage IV Refractory pMMR - MSS CRC, and Other Metastatic G... | PHASE2 | Active Not Recruiting | 107 |
| NCT04827953 | Study to Evaluate the Safety and Efficacy of Treatment With NLM-001 and Standard Chemotherapy Plus Zalifrelimab in Patie... | PHASE2 | Active Not Recruiting | 28 |
| NCT06782932 | Comparing Neoadjuvant/Adjuvant GVAX vs a mKRASvax Given With Anti-PD-1 and Anti-CD137 for Surgically Resectable Pancreat... | PHASE2 | Recruiting | 38 |
| NCT06268015 | Botensilimab and Balstilimab Optimization in Colorectal Cancer | PHASE2 | Active Not Recruiting | 16 |
| NCT06300463 | Platform Study of Immunotherapy Combinations in Colorectal Cancer Liver Metastases | PHASE2 | Recruiting | 24 |
| NCT05529316 | A Study of Botensilimab (AGEN1181) for the Treatment of Advanced Melanoma | PHASE2 | Active Not Recruiting | 150 |
| NCT05891821 | Assessment of the Safety and Efficacy of Balstilimab for the Treatment of Relapsed/Refractory Lymphomas (IMMONC0001) | PHASE2 | Recruiting | 20 |
| NCT06322108 | Assessment of the Safety and Efficacy of Balstilimab in Combination With Botensilimab for the Treatment of Non-Small Cel... | PHASE2 | Active Not Recruiting | 45 |
| NCT03860272 | Fc-Engineered Anti-CTLA-4 Monoclonal Antibody in Advanced Cancer | PHASE1 | Active Not Recruiting | 499 |
| NCT06411691 | KRAS-Targeted Vaccine Combined With Balstilimab and Botensilimab for Patients With Stage IV MMR-p Colorectal Cancer and ... | PHASE1 | Recruiting | 54 |
| NCT07128355 | Botensilimab, Balstilimab, and SBRT in Colorectal Cancer | PHASE1 | Recruiting | 15 |
Source: ClinicalTrials.gov. Trial status last updated by sponsor — may not reflect current state.